 Baton Rouge, LA, Oct. 04, 2021 GLOBE NEWSWIRE -- Adhera Therapeutics, Inc. OTCPK: ATRX Adhera or the Company, a clinical stage biopharmaceutical company, is pleased to announce that a new European patent has been issued for MLR-1019 armesocarb, a drug licensed by the Company from Melior Discovery Melior company Melior Pharmaceuticals II, LLC Melior 2. Melior has received notice from the European Patent Office that the patent, titled, Methods of Treating Dyskinesia and Related Disorders, passed the required period without any opposition being filed, triggering the issuance of the patent. 